These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 1556836)
1. [Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group]. Akaza H; Kameyama S; Kakizoe T; Kojima H; Koiso K; Aso Y; Niijima T Nihon Hinyokika Gakkai Zasshi; 1992 Feb; 83(2):183-9. PubMed ID: 1556836 [TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Akaza H; Hinotsu S; Aso Y; Kakizoe T; Koiso K Cancer; 1995 Jan; 75(2):552-9. PubMed ID: 7812924 [TBL] [Abstract][Full Text] [Related]
4. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors]. Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855 [TBL] [Abstract][Full Text] [Related]
5. BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder. Akaza H Eur Urol; 1995; 27 Suppl 1():9-12. PubMed ID: 7750530 [TBL] [Abstract][Full Text] [Related]
6. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504 [TBL] [Abstract][Full Text] [Related]
7. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect]. Yamamoto T; Hagiwara M; Nakazono M; Yamamoto H Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):997-1001. PubMed ID: 2214478 [TBL] [Abstract][Full Text] [Related]
8. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin]. Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120 [TBL] [Abstract][Full Text] [Related]
9. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686 [TBL] [Abstract][Full Text] [Related]
10. [Analyses of the effects of intravesical Bacillus Calmette-Guerin (Tokyo 172 strain) therapy of superficial bladder cancer]. Akaza H; Kameyama S; Koiso K; Kakizoe T; Kojima H; Umeda T; Kawabe K; Fujita K; Nishimura Y; Yokoyama M Nihon Hinyokika Gakkai Zasshi; 1989 Feb; 80(2):167-74. PubMed ID: 2747081 [TBL] [Abstract][Full Text] [Related]
11. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Akaza H; Koiso K; Ozono S; Kuroda M; Kameyama S; Okajima E; Kotake T; Kakizoe T; Kawabe K; Jpn J Clin Oncol; 2003 Aug; 33(8):382-90. PubMed ID: 14523057 [TBL] [Abstract][Full Text] [Related]
12. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin. Shinka T; Hirano A; Uekado Y; Ohkawa T Br J Urol; 1990 Jul; 66(1):35-9. PubMed ID: 2393797 [TBL] [Abstract][Full Text] [Related]
13. [Experimental and clinical study of intravesical BCG therapy. The role in the prevention of recurrence of superficial bladder tumor]. Hirano A Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1052-61. PubMed ID: 1507722 [TBL] [Abstract][Full Text] [Related]
15. [Intravesical bacillus Calmette-Guerin instillation therapy in superficial bladder cancers--clinical study on prognostic factors]. Shinka T; Hirano A; Uekado Y; Ohkawa T Nihon Hinyokika Gakkai Zasshi; 1990 Mar; 81(3):425-32. PubMed ID: 2359220 [TBL] [Abstract][Full Text] [Related]
16. [Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guerin (BCG) instillation]. Tachibana M; Nakamura S; Jitsukawa S; Deguchi N; Baba S; Hata M; Tazaki H Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):656-61. PubMed ID: 8492508 [TBL] [Abstract][Full Text] [Related]
17. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y; Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576 [TBL] [Abstract][Full Text] [Related]
18. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin. Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer. Takashi M; Wakai K; Ohno Y; Murase T; Miyake K Int Urol Nephrol; 1995; 27(6):723-33. PubMed ID: 8725038 [TBL] [Abstract][Full Text] [Related]
20. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]